News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
497,585 Results
Type
Article (10257)
Company Profile (158)
Press Release (487265)
Multimedia
Podcasts (25)
Webinars (7)
Section
Business (171308)
Career Advice (365)
Deals (26352)
Drug Delivery (16)
Drug Development (54385)
Employer Resources (22)
FDA (10094)
Job Trends (8959)
News (244307)
Policy (18441)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (5)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (593)
Accelerated approval (28)
ADA (22)
Adcomms (2)
Allergies (100)
Alliances (34415)
ALS (108)
Alzheimer's disease (1016)
Antibody-drug conjugate (ADC) (300)
Approvals (10669)
Artificial intelligence (355)
ASCO (167)
Autoimmune disease (216)
Automation (32)
Bankruptcy (269)
Best Places to Work (7153)
BIO (42)
BIOSECURE Act (3)
Biosimilars (132)
BioSpace Insights (27)
Biotechnology (99)
Bladder cancer (142)
Brain cancer (35)
Breast cancer (521)
Cancer (3823)
Cardiovascular disease (233)
Career advice (296)
Career pathing (2)
CAR-T (190)
CDC (4)
Celiac Disease (1)
Cell therapy (531)
Cervical cancer (38)
Clinical research (48918)
Collaboration (1368)
Commercialization (3)
Company closure (4)
Compensation (1479)
Complete response letters (37)
COVID-19 (918)
CRISPR (70)
C-suite (828)
Cystic fibrosis (90)
Data (5792)
Denatured (10)
Depression (111)
Dermatology (62)
Diabetes (362)
Diagnostics (4323)
Digital health (38)
Diversity (2)
Diversity, equity & inclusion (4)
Drug discovery (187)
Drug pricing (21)
Drug shortages (3)
Duchenne muscular dystrophy (193)
Earnings (74365)
Editorial (13)
Employer branding (3)
Employer resources (20)
Events (89239)
Executive appointments (757)
FDA (12751)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (1053)
Gene editing (143)
Generative AI (12)
Gene therapy (371)
GLP-1 (361)
Government (1123)
Grass and pollen (2)
Guidances (285)
Healthcare (9544)
Hematology (95)
HIV (55)
Huntington's disease (24)
IgA nephropathy (67)
Immunology and inflammation (138)
Immuno-oncology (69)
Indications (158)
Infectious disease (1126)
Inflammatory bowel disease (136)
Inflation Reduction Act (9)
Influenza (91)
Intellectual property (261)
Interviews (47)
IPO (12592)
IRA (7)
Job creations (2140)
Job search strategy (281)
JPM (5)
Kidney cancer (20)
Labor market (12)
Layoffs (111)
Leadership (3)
Legal (5296)
Licensing (7)
Liver cancer (50)
Longevity (19)
Lung cancer (526)
Lymphoma (258)
Machine learning (30)
Management (7)
Manufacturing (578)
Marketing (8)
MASH (124)
Medical device (8750)
Medtech (8893)
Mergers & acquisitions (14814)
Metabolic disorders (770)
mRNA (68)
Multiple sclerosis (106)
NASH (6)
Neurodegenerative disease (242)
Neuropsychiatric disorders (51)
Neuroscience (1937)
NextGen: Class of 2026 (3347)
Non-profit (961)
Now hiring (15)
Obesity (262)
Opinion (32)
Ovarian cancer (161)
Pain (181)
Pancreatic cancer (213)
Parkinson's disease (211)
Partnered (15)
Patents (488)
Patient recruitment (522)
Peanut (32)
People (42895)
Pharmaceutical (31)
Pharmacy benefit managers (8)
Phase 1 (15944)
Phase 2 (21912)
Phase 3 (14791)
Pipeline (7500)
Policy (35)
Postmarket research (1583)
Preclinical (6738)
Press Release (34)
Prostate cancer (191)
Psychedelics (15)
Radiopharmaceuticals (201)
Rare diseases (639)
Real estate (3257)
Recruiting (10)
Regulatory (15327)
Reports (25)
Research institute (687)
Resumes & cover letters (53)
Rett syndrome (41)
RNA editing (8)
RSV (52)
Schizophrenia (111)
Series A (195)
Series B (140)
Service/supplier (5)
Sickle cell disease (65)
Special edition (3)
Spinal muscular atrophy (90)
Sponsored (6)
Startups (2292)
Stomach cancer (5)
Supply chain (52)
Tariffs (3)
The Weekly (14)
Vaccines (384)
Venture capital (37)
Weight loss (105)
Women's health (83)
Worklife (1)
Date
Today (38)
Last 7 days (300)
Last 30 days (1743)
Last 365 days (19856)
2026 (12750)
2025 (20046)
2024 (23664)
2023 (27282)
2022 (35574)
2021 (38289)
2020 (34553)
2019 (24065)
2018 (18159)
2017 (19384)
2016 (18554)
2015 (24838)
2014 (22071)
2013 (18604)
2012 (20697)
2011 (20859)
2010 (20701)
Location
Africa (251)
Alabama (76)
Alaska (2)
Arizona (306)
Arkansas (11)
Asia (19053)
Australia (2292)
California (12275)
Canada (3187)
China (582)
Colorado (489)
Connecticut (417)
Delaware (212)
Europe (27326)
Florida (1802)
Georgia (380)
Hawaii (4)
Idaho (47)
Illinois (722)
India (54)
Indiana (323)
Iowa (15)
Japan (406)
Kansas (111)
Kentucky (31)
Louisiana (29)
Maine (26)
Maryland (1220)
Massachusetts (8055)
Michigan (312)
Minnesota (572)
Mississippi (5)
Missouri (85)
Montana (20)
Nebraska (11)
Nevada (116)
New Hampshire (63)
New Jersey (2667)
New Mexico (12)
New York (2843)
North Carolina (1294)
North Dakota (4)
Northern California (6172)
Ohio (292)
Oklahoma (15)
Oregon (19)
Pennsylvania (2263)
Puerto Rico (21)
Rhode Island (31)
South America (424)
South Carolina (76)
South Dakota (1)
Southern California (5055)
Tennessee (125)
Texas (1978)
United States (39667)
Utah (364)
Vermont (1)
Virginia (159)
Washington D.C. (41)
Washington State (982)
West Virginia (2)
Wisconsin (85)
Wyoming (1)
497,585 Results for "greenlight biosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Approvals
Third time’s the charm for Replimune as melanoma drug earns FDA greenlight
Replimune’s immunotherapy for advanced melanoma faced a perilous regulatory road with two previous rejections, but the drug—to be marketed as Tudriqev—prevailed with strong support from oncologists and a 10-3 advisory committee vote in its favor.
August 6, 2026
·
3 min read
·
Heather McKenzie
Approvals
Viridian debuts on market with FDA greenlight for thyroid eye disease drug
Viridian Therapeutics’ Lumvoa is the first FDA-approved treatment for thyroid eye disease that includes data for both active and chronic forms of the illness.
June 29, 2026
·
2 min read
·
Tristan Manalac
Gene therapy
Rocket’s Gene Therapy Wins FDA Greenlight, Clearing Way for Future Products
While the accelerated approval unlocks only a small market opportunity for Rocket Pharmaceuticals, it will give the biotech a chance to prepare for future product launches, according to Jefferies.
March 27, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
August 4, 2026
·
14 min read
Mergers & acquisitions
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
The star of the takeover is Forte Biosciences’ investigational antibody therapy, FB102, which has shown early potential in vitiligo and celiac disease.
July 27, 2026
·
2 min read
·
Tristan Manalac
Press Releases
FDA Greenlights RevBio’s Pivotal Clinical Trial for its Cranial Flap Bone Glue
January 29, 2026
·
3 min read
Rare diseases
FDA Greenlights First Gene Therapy for Rare Pediatric Disease
Backed by Italy-based Fondazione Telethon ETS, Waskyra, for Wiskott-Aldrich syndrome, is the first gene therapy from a non-profit sponsor to win FDA approval.
December 10, 2025
·
1 min read
·
Tristan Manalac
Press Releases
argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
August 6, 2026
·
10 min read
Pain
Lexicon Opens Path to $1B+ Opportunity as FDA Greenlights Phase III for Non-Opioid Pill
The company also stands to gain from recent regulatory FDA guidance aimed at streamlining the development of non-opioid painkillers, Jefferies analysts suggested.
January 22, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026
August 6, 2026
·
7 min read
1 of 49,759
Next
